An FDA panel just overruled its own scientists on six peptides

This week the FDA’s outside advisers on compounding did something they rarely do out loud: they told the agency it was wrong.

On July 23 and 24, the Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides and voted to recommend six of them (BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon) for the list of bulk substances that compounding pharmacies are allowed to prepare. It rejected the seventh, emideltide (also called DSIP). The FDA’s own scientific staff had recommended against all seven.

That is genuinely significant, and being widely misdescribed. What actually happened is narrower than the headlines.

What a PCAC recommendation actually is

The PCAC is a panel of outside scientists and clinicians that advises the FDA. It does not write rules. It votes, and the FDA decides what to do with the vote.

Getting a peptide legally compoundable involves three separate steps, easy to mistake for one another:

1. Removal from Category 2. In April 2026, these peptides came off the FDA’s “do not compound” list, but only because the original nominations were withdrawn, leaving them in a regulatory gray zone. That alone authorizes nothing.
2. A PCAC recommendation. This is the step that happened this week. It is advice, not law.
3. Formal FDA rulemaking. For any of these peptides to actually land on the Section 503A Bulks List, the one that makes compounding lawful, the FDA has to run a full notice-and-comment rulemaking and publish a final rule. That has not happened for any of them.

Two claims need correcting. The FDA did not approve these peptides; approval is an entirely different process involving clinical trials, and none of these has been through it. And the FDA has not moved them into Category 1, the “may be compounded pending final rulemaking” tier. Legal analysts following the docket put the realistic timeline at eight to twelve months of rulemaking before a 503A pharmacy would have clear authority to compound any of these, and that assumes the FDA agrees with its advisers, which it is not required to do.

The vote, peptide by peptide

The committee reviewed each peptide against one or more specific proposed uses, across both days:

Peptide	Reviewed for	Vote	Outcome
BPC-157	ulcerative colitis	8–6, 1 abstention	Recommended
KPV	wound healing, inflammatory conditions	8–6, 1 abstention	Recommended
TB-500	wound healing	8–6, 1 abstention	Recommended
MOTS-c	obesity, osteoporosis	7–5, 2 abstentions	Recommended
Semax	cerebral ischemia, migraine, trigeminal neuralgia	8–5, 1 abstention	Recommended
Epitalon	insomnia	7–5, 1 abstention	Recommended
Emideltide (DSIP)	insomnia, narcolepsy, opioid withdrawal	6–7, 1 abstention	Rejected

None of these votes was lopsided; the closest thing to a consensus was a three- or four-vote margin, and several were decided by two. This was a divided panel, not a rubber stamp. The single rejection, emideltide, failed by one vote. An FDA official summarized the staff’s concern on that one bluntly: there is “a lack of safety and efficacy data to support using emideltide for treating insomnia, narcolepsy and opioid use disorder.”

The disagreement matters more than the vote counts

The part that will still matter a year from now: the committee recommended six peptides that the FDA’s own scientific staff had reviewed and advised against.

The staff’s objection was consistent: not that these compounds are proven dangerous, but that the human evidence is thin to absent. On BPC-157, the only human study on the reviewed use that FDA staff identified enrolled roughly 46 people. On KPV, staff reported finding no completed human trials at all. That is the pattern across most of this list: striking animal data, a devoted following, and a human evidence base that hasn’t caught up.

The advisers recommended most of them anyway. Reasonable people read that two ways. One reading is that the 2023 restrictions were heavier than the actual risk warranted, and that patients and clinicians already using these compounds deserve a regulated, tested supply. The other is that a recommendation ahead of the evidence puts market demand in front of the data. Which reading is right isn’t ours to declare. But this is the genuine fault line, and anyone selling you certainty in either direction is selling something.

Who was in the room, and what’s pushing this

Several forces are pushing this.

• The political backdrop. HHS Secretary Robert F. Kennedy Jr. has publicly favored loosening peptide restrictions and widening access. That is the climate this vote happened in, and whether it shaped the result is a fair question, though the same panel rejected one peptide outright and split narrowly on the others, which cuts against any idea that politics simply steamrolled the evidence.
• The commercial interest. Telehealth companies, including Hims & Hers and Noom, advocated for these peptides during the proceedings. Financial analysts have floated a market on the order of $2.2 billion if compounding is authorized.
• The dissent. Dr. Elizabeth Rebello of MD Anderson said she was “concerned that we’re responding to a market-induced demand rather than a decision based in solid science.” Dr. Peter Lurie, a former FDA associate commissioner, argued that easy compounding “removes incentives to go through FDA’s rigorous drug approval process.” Nina Zeldes of Public Citizen called the evidence “largely based on anecdotal evidence.”

We report the backdrop and the dissent; neither, on its own, tells you whether the panel got the science right. Both belong in a fair picture of a split decision.

What happens next

The FDA now reviews its advisers’ recommendations and decides whether to open rulemaking. If it does, expect a proposed rule in the Federal Register, a public comment period, the agency’s response to comments, and only then a final rule. The FDA can also decline to follow the recommendation entirely.

As we said back in February, when the first reclassification signals started moving markets: the Federal Register is the ground truth, and a press cycle is not a rule. We also wrote then that the most likely outcome would be a substance-by-substance reclassification, because the evidence differs so much from one peptide to the next. This week’s split votes look exactly like that, a panel treating BPC-157 differently from emideltide because the records are different. The process is beginning, roughly as we predicted, and still not a rule.

What this changes for you today

Legally, nothing changed this week. As of today:

• None of these seven peptides is FDA-approved for the uses discussed.
• This vote does not, by itself, make it lawful for a 503A pharmacy to compound any of them.
• A pharmacy that resumes compounding these on the strength of an advisory vote, before a final rule, is operating ahead of the FDA’s published position.

If you are a patient using or considering one of these, the move is unchanged: talk with your prescriber about the regulatory status and the human evidence, and be skeptical of any seller citing this vote as a green light. If you are a clinician fielding questions, the straight answer is that an advisory committee recommended six of seven peptides, the FDA has not acted, and lawful access has not changed.

What we’re watching next

This vote begins something; it doesn’t settle it. A few concrete signposts we’ll track:

• A proposed rule in the Federal Register naming the 503A bulks list. That first legally binding step, not this week’s vote, starts the public-comment clock.
• Whether the FDA follows its own panel. It can adopt all six recommendations, some, or none, and it can judge each peptide on its own record, since the evidence differs sharply from one to the next.
• The next PCAC meeting. Another session, expected by February 2027, is set to weigh additional peptides; this story runs past a single meeting.
• Whether sellers jump the gun. Any pharmacy or telehealth service compounding these now and citing this vote is operating ahead of the FDA, a compliance risk worth flagging to patients.

We’ll watch for the rule itself, not the next press cycle, and report it in full the week it lands. Until then, treat this as what it is: a recommendation worth understanding, and nothing more.

— The Editors

---

About these peptides and their status

BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide (DSIP) are not FDA-approved for the uses described in this letter. The July 2026 PCAC vote was a non-binding recommendation to the FDA; it is not an approval, does not place any of these substances in Category 1, and does not by itself authorize compounding. Emideltide (DSIP) was not recommended. Any use of these peptides outside an FDA-approved indication — and they have none for these uses — is described here for educational purposes only, never as a recommendation. Compounded drugs have not undergone FDA review for safety, efficacy, or manufacturing quality.

Medical disclaimer

This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.